GAO Report Blasts Plan B Review, Bolsters Arguments of Political Meddling

Drug Industry Daily
KEYWORDS FDA / OTC
A A

An unreleased federal report bolsters allegations that the FDA made a political rather than a scientific decision when it delayed Barr Pharmaceuticals’ application to sell the Plan B contraceptive without a prescription, congressional sources say.

To View This Article:

Login

Subscribe To Drug Industry Daily